Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute of Rheumatology will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Woman holding her stomach appearing to be in pain

The intestine is one of the largest immune organs in the body. When healthy, it is regulated by a complex communication network which ensures that the intestinal immune cells peacefully co-exist with the large number of microbes that inhabit the gut.

When there is disruption to any of the communication pathways, the wall of the intestinal wall can become inflamed and inflammatory bowel diseases (IBDs), encompassing Crohn's disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDu), can develop.

There is no cure for IBD and patients can go through unpredictable periods of relapse and remission. Genes, diet and other environmental factors all play a part meaning the disease is never the same for any patient and the response to therapies can vary, with more than 1 out of 2 patients not responding to treatment in the long-term. For this reason, personalised therapies are not standard practise for IBD.

"In a previous study we were able to group patients with IBD, that do not respond well to current therapies, based on their cellular and molecular characteristics or 'pathotype'", said Professor Dame Fiona Powrie, Director of the Kennedy Institute of Rheumatology. "The MRC funding will enable us build on this work and characterise these IBD pathotypes in more detail. By understanding the pathotypes of different patient groups, we move towards being able to discover and direct new therapies to those most likely to benefit."

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Study challenges conventional understanding of household air pollution's impact on fetal growth

In a ground-breaking study published today in Lancet Global Health, researchers present findings challenging conventional wisdom regarding the impact of household air pollution on fetal growth. The study, conducted in 3200 households across resource-poor settings in Guatemala, India, Rwanda, and Peru, focused on assessing the effects of reducing personal exposures to household air pollution on fetal growth in a randomized controlled trial.